---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-003041"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2023-01-11T23:59:59+00:00"
generated_at: "2026-06-20T16:25:09.650905+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Brainstorm Cell Therapeutics annual meeting elects directors and ratifies auditor

## Summary
- Seven nominees elected to Board: Arbel, Almenoff, Polverino, Frenkel, Taub, Yablonka, Bairu; each received >10M votes for.
- Ratification of Brightman Almagor Zohar & Co. (Deloitte) as auditor approved: 23.3M for, 482K against, 66K abstentions.
- Virtual meeting held January 10, 2023; broker non-votes of 13.1M on director elections.

## SEC filing metadata
- accession: 0001104659-23-003041
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2023-01-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465923003041/0001104659-23-003041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465923003041/tm232977d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-003041
- JSON: https://secwatch.observer/filing/0001104659-23-003041.json
- Plain text: https://secwatch.observer/filing/0001104659-23-003041.txt

## Key facts
- Shareholder Votes
  BRAINSTORM CELL THERAPEUTICS INC. shareholders approved Election of seven nominees to the Board of Directors at the 2023-01-10 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-01-10
  source text: 1. The seven nominees (listed below) for election to the Company’s Board of Directors (the “Board”) were elected to hold office until the next annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal, based upon the following votes: Votes For Votes Withheld Votes Against Abstentions Broker Non-Votes Dr. Irit Arbel 10,568,981 226,705 N/A N/A 13,073,706 Dr. June S. Almenoff 10,481,733 313,953 N/A N/A 13,073,706 Dr. Anthony Polverino 10,621,912 173,774 N/A N/A 13,073,706 Dr. Jacob Frenkel 10,637,258 158,428 N/A N/A 13,073,706 Malcolm Taub 10,516,216 279,470 N/A N/A 13,073,706 Uri Yablonka 10,597,289 198,397 N/A N/A 13,073,706 Dr. Menghisteab Bairu 10,652,336 143,350 N/A N/A 13,073,706
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465923003041/0001104659-23-003041-index.htm
- Shareholder Votes
  BRAINSTORM CELL THERAPEUTICS INC. shareholders approved Ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company’s independent registered public accounting firm for the current fiscal year at the 2023-01-10 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-01-10
  source text: The proposal to ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company’s independent registered public accounting firm for the Company’s current fiscal year was approved, based upon the following votes: Votes For Votes Withheld Votes Against Abstentions Broker Non-Votes 23,320,844 N/A 482,449 66,099 N/A
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465923003041/0001104659-23-003041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.